Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Eur J Hosp Pharm ; 30(5): 273-278, 2023 09.
Article in English | MEDLINE | ID: mdl-34649963

ABSTRACT

OBJECTIVES: Medication reconciliation is time-consuming and its complete deployment can be difficult. The implementation of a simplified process, such as patient interviews at admission without full reconciliation, may contribute to improve patient care. The objective of the present study was to describe the feasibility and assess the potential effectiveness of implementing pharmacist-led interviews at patient admission to a rheumatology department. METHODS: This is a prospective observational study of pharmacist-led interviews at patient admission conducted between April 2015 and May 2017 in the 34-bed rheumatology department of Edouard Herriot Hospital, a French university hospital. These interviews were structured to explore patient medication management at home. The main outcome was the number of medication errors at admission. Other outcomes were the total number of interviews, the number of interviews with at least one new item of information provided by the patient, the number of interviews with at least one medication error detected, and the number of interviews leading to a modification of the hospital medication order. RESULTS: A total of 247 interviews were carried out; there was an increase in the number of interviews over the study period (n=54 in 2015, n=98 in 2016, and n=95 for the first 5 months of 2017). Among the interviews conducted, 135 (55%) provided new information concerning patient medication management and 117 medication errors were identified in hospital orders (0.47/patient). There were 76 interviews (31%) with at least one medication error; all led to a medication order modification. CONCLUSIONS: The study found that pharmacist-led interviews at patient admission were effective in detecting medication errors. They could be an alternative to a full medication reconciliation process in targeted situations. When the patient interview does not provide sufficiently robust information, full medication reconciliation may be performed.


Subject(s)
Pharmacy Service, Hospital , Rheumatology , Humans , Patient Admission , Pharmacists , Hospitals, University
2.
BMC Prim Care ; 23(1): 144, 2022 06 03.
Article in English | MEDLINE | ID: mdl-35659194

ABSTRACT

BACKGROUND: To assess current practice regarding the management of rheumatoid arthritis patients among general practitioners of a French region, and their perception about the deployment of a multidisciplinary collaboration. METHODS: A cross-sectional online survey was sent to the general practitioners of a French region. The questionnaire comprised of 3 sections to collect data regarding 1/demographics, 2/practice and knowledge in rheumatoid arthritis, and 3/perception about the deployment of a multidisciplinary collaboration. RESULTS: 1/A total of 247 general practitioners (M/F ratio: 1.4; mean age: 46.7 years) completed the survey. 2/More than half of general practitioners believed that their role was very or extremely important in disease diagnosis (72.5%), and management of comorbidities (67.2%). Among respondents, 6.1% considered that they did not face any difficulty concerning the patient management and 61.5% had already identified causes of non-adherence. 3/A total of 151 (61.1%) general practitioners were willing to participate in a multidisciplinary programme to improve medication adherence in rheumatoid arthritis. CONCLUSIONS: General practitioners are motivated to contribute to an overall management of rheumatoid arthritis patients. Nevertheless, they need professional education about rheumatoid arthritis treatment and training in motivational interviews before getting involved in a multidisciplinary collaboration.


Subject(s)
Arthritis, Rheumatoid , General Practitioners , Arthritis, Rheumatoid/diagnosis , Cross-Sectional Studies , Humans , Middle Aged , Surveys and Questionnaires
3.
Bull Cancer ; 108(6): 643-653, 2021 Jun.
Article in French | MEDLINE | ID: mdl-33902919

ABSTRACT

New anti-cancer therapeutics have been developed in the recent years and dramatically change prognosis and patient management. Either used alone or in combination, immune checkpoint inhibitors (ICI), such as anti-CTLA-4 and anti-PD1/PD-(L)1, act by removing T-cell inhibition to enhance their antitumor response. This change in therapeutic targets leads to a break in immune-tolerance and a unique toxicity profile resulting in immune complications. These side effects, called Immune-Related Adverse Events (IrAEs), can affect all organs, with a wide range of clinical and biological presentations and severity. Various rheumatic and musculoskeletal manifestations have been reported in the literature, ranging from mild arthralgia, polymyalgia rheumatica, to genuine serodefined rheumatoid arthritis and myositis. Tolerance studies suggest some correlations between IrAEs occurrence and tumor response. Assessment of patient musculoskeletal status prior to the start of the ICI is warranted. Management of rheumatic IrAEs does not usually request ICI discontinuation, exception for myositis or very severe forms where it should be discussed. Treatment relies on non-steroidal anti-inflammatory drugs (NSAIDs) or low dose glucocortioids (<20mg per day). Dose should be adjusted according to severity. The use of disease modifying anti-rheumatic drugs (DMARDs), either conventional and/or biological should be very cautious and result from a shared decision between oncologist and rheumatologist to best manage dysimmunitary complications without hampering the antitumor efficacy of ICI.


Subject(s)
Immune Checkpoint Inhibitors/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antirheumatic Agents/therapeutic use , Arthralgia/chemically induced , Arthralgia/drug therapy , Arthritis, Rheumatoid/chemically induced , Arthritis, Rheumatoid/drug therapy , B7-H1 Antigen/antagonists & inhibitors , CTLA-4 Antigen/antagonists & inhibitors , Glucocorticoids/administration & dosage , Humans , Myositis/chemically induced , Myositis/drug therapy , Polymyalgia Rheumatica/chemically induced , Polymyalgia Rheumatica/drug therapy , T-Lymphocytes/drug effects
4.
Joint Bone Spine ; 88(3): 105123, 2021 05.
Article in English | MEDLINE | ID: mdl-33346108

ABSTRACT

INTRODUCTION: Given the prevalence and costs induced by osteoarthritis (OA), it is necessary to find a cheap and safe technique to evaluate it reliably. OBJECTIVE: To assess the value of the lateral dual energy X-ray absorptiometry (DXA) spine scans for the diagnosis of disc degeneration. METHOD: Seventy-seven individuals aged 18 and over, with or without disc degeneration, had both lateral thoracolumbar spine radiographs and DXA spine scans (≤6months between both exams). Disc degeneration was assessed using the Lane score. The images of 20 randomly selected individuals were assessed by two readers. RESULTS: Almost 13% of the thoracic levels were not assessable on the DXA scans. For the identification of the intervertebral levels on the DXA scans as interpretable or not, the intra-reader agreement was good (κ=0.81) and the inter-reader agreement was fair (κ=0.27-0.36). For the diagnostic criteria (osteophytes, disc space narrowing, osteosclerosis, overall grade), the intra-reader agreement was excellent for the radiographs (κ=0.89-0.92), good for the DXA scans (κ=0.64-0.83) and fair to moderate for the between-method comparison (κ=0.25-0.44). The inter-reader agreement was moderate to good for the radiographs (κ=0.49-0.66) and fair to good for the DXA scans (κ=0.32-0.74). In the per patient analysis (the most severe grade), the intra-reader agreement was excellent for the radiographs (κ=0.85-0.94), moderate to excellent for the DXA scans (κ=0.53-0.85) and poor to good for the between-methods comparison (κ=0.17-0.63). CONCLUSION: Our results do not support the use of DXA scans for the assessment of thoracolumbar disc degeneration.


Subject(s)
Intervertebral Disc Degeneration , Absorptiometry, Photon , Adolescent , Adult , Humans , Intervertebral Disc Degeneration/diagnostic imaging , Observer Variation , Reproducibility of Results , Spine
5.
Rheumatology (Oxford) ; 60(5): 2197-2205, 2021 05 14.
Article in English | MEDLINE | ID: mdl-33200181

ABSTRACT

OBJECTIVE: To analyse the risk of incident vertebral and non-vertebral fracture in men with DISH. METHODS: In 782 men ages 50-85 years, DISH was diagnosed using Resnick's criteria. In men followed prospectively for 7.5 years, a radiographic incident vertebral fracture was defined by a decrease of ≥20% or ≥4mm in any vertebral height vs baseline. Self-reported incident non-vertebral fractures were confirmed by medical records. RESULTS: Men with DISH had higher BMD at the lumbar spine (P < 0.05), but not at other skeletal sites. After adjustment for confounders including disc space narrowing (DSN) and endplate irregularity, the risk of vertebral fracture was higher in men with DISH vs men without DISH [10/164 (6.1%) vs 16/597 (2.7%), P < 0.05; odds ratio (OR) 2.89 (95% CI 1.15, 7.28), P < 0.05]. DISH and low spine BMD were each associated with a higher vertebral fracture risk. The vertebral fracture risk was higher in men who had both DISH and severe DSN. DISH and endplate irregularities (EIs) were each associated with higher vertebral fracture risk. DISH, DSN and EIs define the intervertebral space dysfunction, which was associated with higher vertebral fracture risk [OR 3.99 (95% CI 1.45, 10.98), P < 0.01]. Intervertebral space dysfunction improved the vertebral fracture prediction (ΔAUC = +0.111, P < 0.05), mainly in men with higher spine BMD (>0.9 g/cm2; ΔAUC = +0.189, P < 0.001). DISH was not associated with the risk of non-vertebral fracture. CONCLUSION: DISH is associated with higher vertebral fracture risk, independently of other risk factors. Assessment of the intervertebral space dysfunction components may improve the vertebral fracture prediction in older men.


Subject(s)
Bone Density/physiology , Hyperostosis, Diffuse Idiopathic Skeletal/epidemiology , Spinal Fractures/epidemiology , Aged , Aged, 80 and over , Comorbidity , Humans , Hyperostosis, Diffuse Idiopathic Skeletal/diagnostic imaging , Incidence , Male , Middle Aged , Prospective Studies , Radiography , Risk , Spinal Fractures/diagnostic imaging
6.
Eur J Intern Med ; 59: 91-96, 2019 01.
Article in English | MEDLINE | ID: mdl-30482636

ABSTRACT

BACKGROUND: Pharmacists contribute to reduce the number of medication errors during medication review. Nevertheless, few French studies report the potential clinical impact of pharmacists' interventions performed after detecting drug-related problems. The objective was to evaluate the clinical relevance of pharmacists' interventions in a rheumatology ward from medical and pharmaceutical perspectives. METHOD: The analysis was conducted on pharmacists' interventions performed between January 1 and December 31, 2015 in a French teaching hospital. Similar pharmacists' interventions were grouped in one item and they were analysed according to 11 drug categories. The clinical significance of pharmacists' interventions was considered independently by a pharmacist and a rheumatologist using a validated French scale that categorises drug-related problems from minor to catastrophic. The agreement between the two professionals was analysed using the weighted kappa coefficient. RESULTS: Of 1313 prescriptions reviewed, 461 pharmacists' interventions (171 items) were formulated for drug-related problems with an acceptance rate of 67.2%. Of the 418 interventions selected for clinical significance analysis, 235 interventions (56.2%) for the physician and 400 interventions (95.7%) for the pharmacist were at least significant. The two professionals evaluated equally the clinical relevance of 90 items (50.6%). The categories with the most similarities were the analgesics/anti-inflammatory drugs (78.1%), the antidiabetics (75.0%) and the anticoagulants (71.4%). The agreement was estimated by a weighted kappa coefficient of 0.29. CONCLUSION: This work highlights the positive clinical relevance of pharmacists' interventions in rheumatology and the importance of medico-pharmaceutical collaboration to prevent medication errors.


Subject(s)
Drug Prescriptions/statistics & numerical data , Medication Errors/prevention & control , Medication Errors/statistics & numerical data , Pharmacists/statistics & numerical data , Pharmacy Service, Hospital/statistics & numerical data , Rheumatology , Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , France , Hospital Units , Hospitals, Teaching , Humans , Male , Middle Aged , Physicians/statistics & numerical data , Professional Role , Retrospective Studies , Young Adult
7.
Rheumatology (Oxford) ; 56(1): 37-45, 2017 01.
Article in English | MEDLINE | ID: mdl-27703044

ABSTRACT

OBJECTIVE: Data on the relationship between disc degeneration (DD) and fragility fractures in men are limited. The aim of this study was to prospectively analyse the risk of vertebral and non-vertebral fractures in men with thoracolumbar DD according to the severity of its radiological signs: disc space narrowing (DSN), osteophytes and endplate sclerosis. METHODS: Men >50 years of age (n = 765) had lateral spine radiographs and DXA and were monitored prospectively. We analysed the risk of incident vertebral (7.5 years) and non-vertebral fractures (10 years) in men according to the severity of DD. RESULTS: After adjustment for age and weight, BMD increased with increasing total DSN score, endplate sclerosis and osteophytosis. Over 7.5 years, 28 incident vertebral fractures occurred in 27 men. After adjustment for age, BMI, spine BMD, prior fractures and abdominal aortic calcifications, the vertebral fracture risk was 3-fold higher in the upper DSN quartile vs men without DSN. After adjustment for the same confounders, vertebral fracture risk was also nearly 3-fold higher in the upper DSN quartile vs the three lower quartiles combined. Over 10 years, 61 men sustained non-vertebral fragility fractures. After adjustment for age, BMI, hip BMD, abdominal aortic calcifications and prior falls and fractures, the non-vertebral fracture risk decreased with increasing DSN score. The risk of non-vertebral fracture was half as high in men above the median total DSN score vs men below the median. CONCLUSION: In older men, severe DD is associated with higher BMD. Multilevel severe DSN is associated with higher vertebral fracture risk and lower non-vertebral fracture risk.


Subject(s)
Intervertebral Disc Degeneration/epidemiology , Lumbar Vertebrae/injuries , Spinal Fractures/epidemiology , Thoracic Vertebrae/injuries , Absorptiometry, Photon , Aged , Aged, 80 and over , Aorta, Abdominal/diagnostic imaging , Aortic Diseases/diagnostic imaging , Aortic Diseases/epidemiology , Bone Density , Cohort Studies , Fractures, Bone/epidemiology , France/epidemiology , Humans , Incidence , Intervertebral Disc Degeneration/diagnostic imaging , Lumbar Vertebrae/diagnostic imaging , Male , Middle Aged , Osteophyte/diagnostic imaging , Osteophyte/epidemiology , Prospective Studies , Radiography , Risk Factors , Severity of Illness Index , Thoracic Vertebrae/diagnostic imaging , Vascular Calcification/diagnostic imaging , Vascular Calcification/epidemiology
8.
Arthritis Rheumatol ; 67(5): 1295-304, 2015 May.
Article in English | MEDLINE | ID: mdl-25772505

ABSTRACT

OBJECTIVE: To assess the association of disc degeneration with all-cause mortality and with the severity and rate of progression of abdominal aortic calcification (AAC) in older men. METHODS: Men >50 years of age (n = 766) underwent lateral spine radiography and blood collection and were monitored prospectively. We assessed the association of disc degeneration with all-cause mortality (at 10 years), AAC severity (at baseline), and AAC progression (at 7.5 years). RESULTS: After adjustment for confounders, including AAC, the total overall grade score for AAC predicted all-cause mortality (hazard ratio [HR] 1.20 per SD increase [95% confidence interval (95% CI) 1.01-1.43]). The highest tertile of the total overall grade score was associated with higher mortality rates (39.3/1,000 person-years for a score of >8 versus 20.9/1,000 person-years for a score of 0-8; adjusted HR 1.47 [95% CI 1.05-2.06]). The odds of severe AAC (score of >5) increased with the total disc space narrowing score (adjusted HR 1.44 per SD [95% CI 1.11-1.87]). The highest tertile of the total disc space narrowing score was associated with higher odds of severe AAC (adjusted HR 2.42 versus the lowest tertile [95% CI 1.24-4.73]). The probability of long-term AAC stability decreased with an increasing total osteophyte score (adjusted HR 0.66 per SD [95% CI 0.49-0.88]). The highest tertile of the total osteophyte score was associated with a lower probability of AAC stability (adjusted HR 0.35 versus the lowest tertile [95% CI 0.18-0.71]). CONCLUSION: Older men with severe disc degeneration have greater AAC severity, faster AAC progression, and higher all-cause mortality rates.


Subject(s)
Aortic Diseases/epidemiology , Intervertebral Disc Degeneration/epidemiology , Mortality , Vascular Calcification/epidemiology , Aged , Aged, 80 and over , Aorta, Abdominal , Aortic Diseases/diagnostic imaging , Disease Progression , Humans , Intervertebral Disc Degeneration/diagnostic imaging , Longitudinal Studies , Male , Middle Aged , Osteoporosis , Prospective Studies , Radiography , Risk Factors , Severity of Illness Index , Vascular Calcification/diagnostic imaging
9.
Joint Bone Spine ; 80(6): 645-9, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23928237

ABSTRACT

Familial Mediterranean fever is an autosomal-recessive autoinflammatory disorder more commonly observed in Mediterranean populations and characterized by recurrent episodes of fever, serositis, myalgia and arthritis. There is rarely any association with spondyloarthritis. The most important long-term complication is progressive systemic type AA amyloidosis. Treatment with colchicine is effective in reducing the frequency of attacks and prevents the development of amyloidosis. However, 5% of cases are considered resistant to colchicine. We here describe the case of a 39-year-old man, with a history of arthritis, arthralgias, and sacroiliitis in the course of a familial Mediterranean fever. He is homozygous for the M694I mutation in the MEFV gene. He subsequently developed myositis of the right quadriceps muscle confirmed by magnetic resonance imaging, electromyography and histology. He had frequent and severe arthralgias, despite colchicine, then etanercept and adalimumab, impairing his quality of life. The patient was successfully treated with the IL-1 receptor antagonist anakinra with a dramatic improvement of muscular and articular symptoms. To our knowledge, our patient is the first patient with coexisting FMF, spondyloarthritis and myositis responding to anakinra treatment. Moreover this is the second case in the literature of myositis associated with familial Mediterranean fever.


Subject(s)
Familial Mediterranean Fever/complications , Myositis/drug therapy , Spondylarthritis/complications , Adult , Antirheumatic Agents/therapeutic use , Familial Mediterranean Fever/genetics , Humans , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Male , Myositis/complications
SELECTION OF CITATIONS
SEARCH DETAIL
...